MiNK Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax
MiNK Therapeutics, Inc. (INKT) reported Other Comprehensive Income (Loss), Net of Tax of -$2.47 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-13
- MiNK Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$2.47K.
- MiNK Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was $21.49K.
- MiNK Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $27.20K.
- MiNK Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-06-30 was -$56.88K.
- MiNK Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2025 was -$87.34K.
- MiNK Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2024 was -$200.63K.
- MiNK Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2023 was -$138.48K, a 141.61% decline from fiscal 2022.
- MiNK Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2022 was $332.80K, a 62.93% decline from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$2.47K 10-Q · filed 2026-08-13 | $19.02K derived: sum of 2 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $21.49K 10-Q · filed 2026-08-13 | ||||
| 2025-12-31 | -$87.34K 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $27.20K 10-Q · filed 2025-11-14 | -$29.67K derived: sum of 2 quarters · filed 2026-08-13 | -$60.54K derived: sum of 3 quarters · filed 2026-08-13 | ||
| 2025-06-30 | -$56.88K 10-Q · filed 2026-08-13 | -$87.74K derived: sum of 2 quarters · filed 2026-08-13 | |||
| 2025-03-31 | -$30.86K 10-Q · filed 2026-08-13 | ||||
| 2024-12-31 | -$200.63K 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | -$61.46K 10-Q · filed 2025-11-14 | -$287.06K derived: sum of 2 quarters · filed 2025-11-14 | -$241.89K derived: sum of 3 quarters · filed 2025-11-14 | ||
| 2024-06-30 | -$225.59K 10-Q · filed 2025-11-14 | -$180.43K derived: sum of 2 quarters · filed 2025-11-14 | |||
| 2024-03-31 | $45.17K 10-Q · filed 2025-11-14 | ||||
| 2023-12-31 | -$138.48K 10-K · filed 2025-03-18 | ||||
| 2023-09-30 | $88.62K 10-Q · filed 2024-11-14 | -$88.62K 10-Q · filed 2023-11-14 | $60.62K derived: sum of 2 quarters · filed 2024-11-14 | -$20.72K derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$28.01K 10-Q · filed 2024-11-14 | -$109.34K derived: sum of 2 quarters · filed 2024-11-14 | |||
| 2023-03-31 | -$81.33K 10-Q · filed 2024-11-14 | ||||
| 2022-12-31 | $332.80K 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | -$1.38M 10-Q · filed 2023-11-14 | $24.22K derived: sum of 2 quarters · filed 2023-11-14 | $546.99K derived: sum of 3 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $1.40M 10-Q · filed 2023-11-14 | $1.92M derived: sum of 2 quarters · filed 2023-11-14 | |||
| 2022-03-31 | $522.77K 10-Q · filed 2023-11-14 | ||||
| 2021-12-31 | $897.77K 10-K · filed 2023-03-24 | ||||
| 2021-09-30 | $546.11K 10-Q · filed 2022-11-03 | $380.40K derived: sum of 2 quarters · filed 2022-11-03 | $733.70K derived: sum of 3 quarters · filed 2022-11-03 | ||
| 2021-06-30 | -$165.71K 10-Q · filed 2022-11-03 | $187.59K derived: sum of 2 quarters · filed 2022-11-03 | |||
| 2021-03-31 | $353.31K 10-Q · filed 2022-11-03 | ||||
| 2020-12-31 | -$1.39M 10-K · filed 2022-03-18 | ||||
| 2020-09-30 | -$803.50K 10-Q · filed 2021-11-29 | -$989.07K derived: sum of 2 quarters · filed 2021-11-29 | -$353.17K derived: sum of 3 quarters · filed 2021-11-29 | ||
| 2020-06-30 | -$185.57K 10-Q · filed 2021-11-29 | $450.33K derived: sum of 2 quarters · filed 2021-11-29 | |||
| 2020-03-31 | $635.90K 10-Q · filed 2021-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |